Pictilisib联合标准化疗方案治疗晚期非小细胞肺癌的IB期剂量递增研究
该IB期剂量递增研究评估pan-PI3K抑制剂pictilisib联合紫杉醇+卡铂或培美曲塞+顺铂(±贝伐珠单抗)一线治疗晚期NSCLC的安全性与药代动力学。66例可评估患者中,所有患者均发生至少1例不良事件,≥III级AE占86.4%,SAE占84.8%,死亡占13.6%。未达到MTD,RP2D为pictilisib 330mg(胶囊)或340mg(片剂),14天给药/7天停药方案;部分缓解29例(43.9%),疾病稳定20例(30.9%)。
要点
- 所有66例患者均发生至少1例AE,≥III级AE 57例(86.4%),SAE 56例(84.8%),死亡9例(13.6%)。
- 四组中仅3例报告DLT,各臂均未达到MTD。
- RP2D为pictilisib 330mg(胶囊)或340mg(片剂),14天给药/7天停药。
核心结论
- Pictilisib联合多种一线标准化疗方案在NSCLC患者中从安全性角度可行,并观察到令人鼓舞的初步抗肿瘤活性。
研究设计与样本
- 3+3剂量递增研究,pictilisib起始日剂量60mg,21天周期中第1-14天给药。
- 根据贝伐珠单抗资格和NSCLC组织学,患者接受紫杉醇+卡铂或培美曲塞+顺铂,±贝伐珠单抗,每3周一次。
- 共66例患者接受治疗。
主要发现
- 四组中仅3例报告DLT;各臂均未达到MTD。
- 最佳确认疗效为部分缓解29例(43.9%),疾病稳定20例(30.9%)。
关键数值与推荐
- RP2D为pictilisib 330mg(胶囊)或340mg(片剂),采用14天给药/7天停药方案。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The phosphatidylinositol 3-kinase (PI3K) pathway is a potential therapeutic target in non-small cell lung cancer (NSCLC). This study aimed to evaluate the pan-PI3K inhibitor pictilisib in combination with first-line treatment regimens that were the standard of care at the time of study, in patients with NSCLC. PATIENTS AND METHODS: A 3 + 3 dose-escalation study was performed using a starting daily dose of 60 mg pictilisib on days 1-14 of a 21-day cycle. Depending on bevacizumab eligibility and NSCLC histology, patients also received either paclitaxel + carboplatin or pemetrexed + cisplatin, ± bevacizumab every 3 weeks. The primary objectives of the study were to assess safety and tolerability and to identify dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D), for each combination. RESULTS: All 66 treated patients experienced at least one adverse event (AE). Grade ≥III AEs, serious AEs and deaths occurred in 57 (86.4%), 56 (84.8%) and 9 (13.6%) patients, respectively. Three patients reported DLTs across the four arms of the study. The MTD was not reached in any arm and the RP2D of pictilisib was determined to be 330 mg (capsules) or 340 mg (tablets) on a '14 days on, 7 days off' schedule. The best confirmed response was partial response in 29 (43.9%) patients and stable disease in 20 (30.9%) patients. CONCLUSION: Combining pictilisib with various standard-of-care first-line treatment regimens is feasible from a safety perspective in patients with NSCLC, and encouraging preliminary anti-tumour activity was observed.
引用
- Soria JC, Adjei AA, Bahleda R, et al. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017. PMID: 28992562. doi:10.1016/j.ejca.2017.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。